We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
Study of changes in lipid profile and fasting blood glucose in protease inhibitor exposed HIV/AIDS patients in School of Tropical Medicine, Kolkata
© Bhowmik et al; licensee BioMed Central Ltd. 2012
- Published: 4 May 2012
- Body Mass Index
- Protease Inhibitor
- Total Cholesterol
The national second-line Anti retroviral Therapy (ART) programme was started in Kolkata in December 2008. It included a combination of Tenofovir, Lamivudine and Ritonavir-boosted Lopinavir ± Zidovudine. Dyslipidaemia and increased fasting blood sugar (FBS) often complicate protease inhibitor-containing ART. Thus a prospective study was designed to observe the above changes.
The data of 48 patients, on protease inhibitor for one year were analyzed. Body Mass Index (BMI), grip strength (GS), Triceps skin fold (TSF), 24 hour dietary recall, serum triglyceride (TG), total cholesterol (TC), HDL, LDL, VLDL and FBS were estimated for all patients at baseline, 6 months and after one year.
There was a significant increase in TG, TC and VLDL levels at 1 year as compared to baseline (p=0.013, 0.00 and 0.00 respectively) whereas LDL significantly increased at 6 months only (p=0.029). HDL decreased significantly at 6 months (p=0.019). TSF significantly decreased both at 6 and 12 months (p=0.00 and 0.00 respectively). The BMI and GS showed a significant increase at both 6 months (p=0.001, 0.000 respectively) and 1 year (p=0.005 and 0.00 respectively). Four patients with normal baseline FBG and one with impaired fasting glucose progressed to overt diabetes (FBG > 124 mg/dl) at 12 months. No significant change was noted in energy and protein intake of patients.
There is an increased incidence of dyslipidaemia and unmasking of diabetes related to protease inhibitor in this cohort. There has been an improvement in nutritional status as shown by BMI and GS.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.